Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Achaogen, Inc.AKAO · Entity 158957 | See Remarks | February 21, 2019 | February 25, 2019 |
| INTUITIVE SURGICAL INCISRG · Entity 2878 | EVP & Chief Legal and Complian | October 10, 2026 | October 13, 2026 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | EVP, General Counsel & Sec. | March 23, 2021 | March 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Achaogen, Inc.
Report date February 21, 2019 · Filed February 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 239,673 |
Reported balance
After 2019-02-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-02-21 · Sale · Disposed 791 · Balance 239,673 F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") of the Issuer. F2: Includes 231,057 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") of the Issuer.
F2: Includes 231,057 RSUs.
INTUITIVE SURGICAL INC
Report date October 10, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,636 |
Ending reported balance
After 2026-10-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-10 · Exercise / conversion · Acquired 2,612 · Balance 7,932 F1: RSUs vest 25% per year over a four year period, commencing on the first anniversary of the grant date. RSUs convert into common stock on the vest date on a one-for-one basis. 25% of the shares have been released and a portion of the shares were held back to cover the tax withholding obligations. The net shares were deposited into the holders account. Row 2 · 2026-10-10 · Tax withholding · Disposed 1,296 · Balance 6,636 F1: RSUs vest 25% per year over a four year period, commencing on the first anniversary of the grant date. RSUs convert into common stock on the vest date on a one-for-one basis. 25% of the shares have been released and a portion of the shares were held back to cover the tax withholding obligations. The net shares were deposited into the holders account. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2026-10-10 | Direct | 0 |
Reported balance
After 2026-10-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-10 · Exercise / conversion · Disposed 2,612 · Balance 0 F2: Each RSU granted represents a contingent right to receive one share of Intuitive Surgical common stock. The grant vests 25% on the first anniversary of the date of grant and annually thereafter, over a four year period. |
Filing footnotes · ownership attribution and instrument terms
F1: RSUs vest 25% per year over a four year period, commencing on the first anniversary of the grant date. RSUs convert into common stock on the vest date on a one-for-one basis. 25% of the shares have been released and a portion of the shares were held back to cover the tax withholding obligations. The net shares were deposited into the holders account.
F2: Each RSU granted represents a contingent right to receive one share of Intuitive Surgical common stock. The grant vests 25% on the first anniversary of the date of grant and annually thereafter, over a four year period.
SANGAMO THERAPEUTICS, INC
Report date March 23, 2021 · Filed March 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 83,238 |
Last balance in matching sequence
After 2021-03-23 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2021-03-23 · Exercise / conversion · Acquired 11,981 · Balance 100,762 F1: Includes 33,335 shares of common stock issuable upon settlement of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 25, 2020 that will vest in two remaining annual installments of 16,665 shares and 16,670 shares on February 25, 2022 and 2023 respectively, and 44,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third anniversary of the date of grant. The vesting of all such RSUs is subject to the Reporting Person's continuous service as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"), through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Row 2 · 2021-03-23 · Sale · Disposed 11,981 · Balance 88,781 F1: Includes 33,335 shares of common stock issuable upon settlement of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 25, 2020 that will vest in two remaining annual installments of 16,665 shares and 16,670 shares on February 25, 2022 and 2023 respectively, and 44,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third anniversary of the date of grant. The vesting of all such RSUs is subject to the Reporting Person's continuous service as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"), through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Row 3 · 2021-03-23 · Sale · Disposed 5,000 · Balance 83,781 F1: Includes 33,335 shares of common stock issuable upon settlement of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 25, 2020 that will vest in two remaining annual installments of 16,665 shares and 16,670 shares on February 25, 2022 and 2023 respectively, and 44,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third anniversary of the date of grant. The vesting of all such RSUs is subject to the Reporting Person's continuous service as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"), through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Row 4 · 2021-03-23 · Sale · Disposed 543 · Balance 83,238 F1: Includes 33,335 shares of common stock issuable upon settlement of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 25, 2020 that will vest in two remaining annual installments of 16,665 shares and 16,670 shares on February 25, 2022 and 2023 respectively, and 44,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third anniversary of the date of grant. The vesting of all such RSUs is subject to the Reporting Person's continuous service as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"), through such dates and subject to acceleration as defined in the 2018 EIP, as amended. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.02 · Expires 2029-08-22 | Direct | 238,019 |
Reported balance
After 2021-03-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-23 · Exercise / conversion · Disposed 11,981 · Balance 238,019 F2: The option vested as to 1/4 of the total grant amount upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person, measured from the August 23, 2019 grant date, and the remainder vest and become exercisable in equal monthly installments for thirty-six months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date and subject to acceleration as provided in the 2018 EIP, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 33,335 shares of common stock issuable upon settlement of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 25, 2020 that will vest in two remaining annual installments of 16,665 shares and 16,670 shares on February 25, 2022 and 2023 respectively, and 44,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third anniversary of the date of grant. The vesting of all such RSUs is subject to the Reporting Person's continuous service as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"), through such dates and subject to acceleration as defined in the 2018 EIP, as amended.
F2: The option vested as to 1/4 of the total grant amount upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person, measured from the August 23, 2019 grant date, and the remainder vest and become exercisable in equal monthly installments for thirty-six months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date and subject to acceleration as provided in the 2018 EIP, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2023 Filed Aug 11, 2023 21:07 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,889 | $0.00 Strike: $304.67 | $0.00 |
DisclosureSEC source: 0001035267-23-000169 · edgardoc.xml · derivative · entry 1 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,889 Underlying: Common Stock · 1,889 shares Expires 2030-08-09 F1 · derivative.exercise_date: 7/48th of the shares subject to the option vest on the one-month anniversary measured from August 10, 2023, and 1/48th of the total number of shares vest in forty-one (41) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 22:56 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | GrantRestricted Stock Units · Derivative | 1,259 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001035267-23-000070 · edgardoc.xml · derivative · entry 2 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,259 Underlying: Common Stock · 1,259 shares Expires not disclosed F2 · derivative.exercise_date: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock upon vesting. 25% of the RSUs shall vest on each anniversary of February 10, 2023, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock upon vesting. 25% of the RSUs shall vest on each anniversary of February 10, 2023, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 22:56 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,889 | $0.00 Strike: $229.39 | $0.00 |
DisclosureSEC source: 0001035267-23-000070 · edgardoc.xml · derivative · entry 1 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,889 Underlying: Common Stock · 1,889 shares Expires 2030-02-27 F1 · derivative.exercise_date: 12.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 21:21 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | GrantRestricted Stock Units · Derivative | 10,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001035267-22-000162 · edgardoc.xml · derivative · entry 1 LOEB GARY · CIK 0001561733 · General Counsel & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,450 Underlying: Common Stock · 10,450 shares Expires 2026-10-10 F1 · derivative.exercise_date: Each RSU granted represents a contingent right to receive one share of Intuitive Surgical common stock. The grant vests 25% on the first anniversary of the date of grant and annually thereafter, over a four year period. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 23:17 UTC Amendment | INTUITIVE SURGICAL INC ISRG · Entity 2878 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,450 | $0.00 Strike: $186.55 | $0.00 |
DisclosureSEC source: 0001567619-22-018459 · doc1.xml · derivative · entry 1 LOEB GARY · CIK 0001561733 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,450 Underlying: Common Stock · 10,450 shares Expires 2029-10-09 F1 · security: The Reporting Person inadvertently omitted the option grant from the original Form 4 filing. This Form 4/A corrects the aforementioned error. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 filed with the Securities and Exchange Commission was accurately reported. F2 · derivative.exercise_date: Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/4th on the first anniversary of the date of grant and 1/48th monthly thereafter. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 23:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right-to-Buy) · Derivative | 11,981 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-21-023085 · doc4.xml · derivative · entry 5 LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,019 Underlying: Common Stock · 11,981 shares Expires 2029-08-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 1/4 of the total grant amount upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person, measured from the August 23, 2019 grant date, and the remainder vest and become exercisable in equal monthly installments for thirty-six months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 23:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 543 | $13.17 | $7,152.02 |
DisclosureSEC source: 0001209191-21-023085 · doc4.xml · nonDerivative · entry 4 LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,238 F1 · balance_after: Includes 33,335 shares of common stock issuable upon settlement of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 25, 2020 that will vest in two remaining annual installments of 16,665 shares and 16,670 shares on February 25, 2022 and 2023 respectively, and 44,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third anniversary of the date of grant. The vesting of all such RSUs is subject to the Reporting Person's continuous service as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"), through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 23:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $13.18 | $65,900.50 |
DisclosureSEC source: 0001209191-21-023085 · doc4.xml · nonDerivative · entry 3 LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,781 F1 · balance_after: Includes 33,335 shares of common stock issuable upon settlement of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 25, 2020 that will vest in two remaining annual installments of 16,665 shares and 16,670 shares on February 25, 2022 and 2023 respectively, and 44,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third anniversary of the date of grant. The vesting of all such RSUs is subject to the Reporting Person's continuous service as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"), through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 23:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 11,981 | $13.10 | $156,989.44 |
DisclosureSEC source: 0001209191-21-023085 · doc4.xml · nonDerivative · entry 2 LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,781 F1 · balance_after: Includes 33,335 shares of common stock issuable upon settlement of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 25, 2020 that will vest in two remaining annual installments of 16,665 shares and 16,670 shares on February 25, 2022 and 2023 respectively, and 44,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third anniversary of the date of grant. The vesting of all such RSUs is subject to the Reporting Person's continuous service as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"), through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 23:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 11,981 | $11.02 | $132,030.62 |
DisclosureSEC source: 0001209191-21-023085 · doc4.xml · nonDerivative · entry 1 LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 33,335 shares of common stock issuable upon settlement of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 25, 2020 that will vest in two remaining annual installments of 16,665 shares and 16,670 shares on February 25, 2022 and 2023 respectively, and 44,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third anniversary of the date of grant. The vesting of all such RSUs is subject to the Reporting Person's continuous service as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"), through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 88,000 | $0.00 Strike: $11.19 | $0.00 |
DisclosureSEC source: 0001209191-21-015517 · doc4.xml · derivative · entry 3 LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 88,000 shares Expires 2031-02-24 F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the February 25, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015517 · doc4.xml · nonDerivative · entry 2 LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,781 F3 · shares: Represents 44,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 5,762 | $11.19 | $64,476.78 |
DisclosureSEC source: 0001209191-21-015517 · doc4.xml · nonDerivative · entry 1 LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,781 F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on February 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 25, 2021 of $11.19/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). F2 · balance_after: Includes: (a) 291 shares of common stock and 252 shares of common stock acquired by the Reporting Person on April 30, 2021 and October 30, 2020, respectively under the Issuer's 2010 Employee Stock Purchase Plan, as amended; and (b) 10,903 shares resulting from the February 25, 2021 vesting of the Reporting Person's February 25, 2020 RSU grant and 33,335 shares subject to such RSU grant that will vest in two remaining annual installments of 16,665 shares and 16,670 shares on February 25, 2022 and 2023 respectively. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:32 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right-to-Buy) · Derivative | 100,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-20-013231 · doc4.xml · derivative · entry 2 LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-24 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:32 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-013231 · doc4.xml · nonDerivative · entry 1 LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Represents 50,000 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 16:54 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right-to-Buy) · Derivative | 100,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-20-013315 · doc4a.xml · derivative · entry 2 LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-24 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 16:54 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-013315 · doc4a.xml · nonDerivative · entry 1 LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Represents 50,000 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Read SEC document |
| August 23, 2019 Filed Feb 3, 2020 22:52 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-20-006107 · doc4.xml · derivative · entry 1 LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-08-22 F1 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the August 23, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 20:42 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 791 | $0.89 | $703.99 |
DisclosureSEC source: 0001567619-19-005387 · doc1.xml · nonDerivative · entry 1 LOEB GARY · CIK 0001561733 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,673 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") of the Issuer. F1 · shares: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") of the Issuer. F2 · balance_after: Includes 231,057 RSUs. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 17:12 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantCommon Stock | 156,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-001516 · doc1.xml · nonDerivative · entry 1 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,464 F1 · shares: Grant of Restricted Stock Units ("RSUs"). The reporting person is entitled to one (1) share of Common Stock for each one(1) RSU upon the vesting thereof. F2 · balance_after: Includes (i) 1,133 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2018 and (ii) 232,030 RSUs. Read SEC document |
| October 31, 2018 Filed Jan 23, 2019 17:06 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-001511 · doc1.xml · nonDerivative · entry 1 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,831 F1 · shares: Grant of Restricted Stock Units ("RSUs"). The reporting person is entitled to one (1) share of Common Stock for each one(1) RSU upon the vesting thereof. F2 · balance_after: Includes 75,530 RSUs. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 20:08 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 1,038 | $4.15 | $4,307.70 |
DisclosureSEC source: 0001567619-18-003254 · doc1.xml · nonDerivative · entry 1 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,831 F1 · kind: The shares were sold solely to satisfy the tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") of the Issuer. F2 · balance_after: Includes 15,530 RSUs. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 14:58 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $4.79 | $0.00 |
DisclosureSEC source: 0001567619-18-002534 · doc1.xml · derivative · entry 1 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-09-11 F1 · derivative.exercise_date: The Shares subject to the option vest in two successive annual installments, with 40% of the Shares subject to the option vesting on September 11, 2019 and 60% of the Shares subject to the option vesting on September 11, 2020, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 16:20 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001140361-18-030424 · doc1.xml · derivative · entry 3 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2028-02-08 F1 · kind: On February 8, 2018, the issuer granted the reporting person Restricted Stock Units ("RSUs") and a stock option that each vest upon the achievement of certain milestones. On June 26, 2018, one of the milestones was achieved, resulting in vesting of a portion of the RSUs and shares subject to the option. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 16:20 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 324 | $9.59 | $3,107.16 |
DisclosureSEC source: 0001140361-18-030424 · doc1.xml · nonDerivative · entry 2 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,869 F3 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of RSUs of the Issuer. F2 · balance_after: Includes (i) 996 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2018 and (ii) 18,530 RSUs. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 16:20 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantCommon Stock | 960 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-030424 · doc1.xml · nonDerivative · entry 1 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,193 F1 · kind: On February 8, 2018, the issuer granted the reporting person Restricted Stock Units ("RSUs") and a stock option that each vest upon the achievement of certain milestones. On June 26, 2018, one of the milestones was achieved, resulting in vesting of a portion of the RSUs and shares subject to the option. F2 · balance_after: Includes (i) 996 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2018 and (ii) 18,530 RSUs. Read SEC document |
| February 08, 2018 Filed May 15, 2018 18:32 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001140361-18-024053 · doc1.xml · derivative · entry 2 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2028-02-08 F3 · derivative.exercise_date: The shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of February 8, 2018, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| February 08, 2018 Filed May 15, 2018 18:32 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantCommon Stock | 7,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-024053 · doc1.xml · nonDerivative · entry 1 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,237 F1 · shares: Grant of Restricted Stock Units ("RSUs"). The reporting person is entitled to one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes (i) 1,174 shares acquired under the issuer's Employee Stock Purchase Plan on November 30, 2017 and (ii) 18,530 Restricted Stock Units. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 18:00 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 1,146 | $15.99 | $18,324.54 |
DisclosureSEC source: 0001140361-17-036830 · doc1.xml · nonDerivative · entry 1 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units of the Issuer. F2 · balance_after: Includes 10,800 Restricted Stock Units. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 21:37 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 521 | $16.78 | $8,742.38 |
DisclosureSEC source: 0001140361-17-003550 · doc1.xml · nonDerivative · entry 1 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,479 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units of the Issuer. F2 · balance_after: Includes 13,800 Restricted Stock Units. Read SEC document |
| November 18, 2016 Filed Nov 23, 2016 19:18 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001140361-16-087818 · doc1.xml · derivative · entry 3 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2026-11-18 F3 · derivative.exercise_date: The shares subject to the option shall vest on the following schedule: (i) 40% of the shares subject to the option will vest on the 30th consecutive date that closing trading price of the Issuer's common stock first reaches or exceeds $12.00 per share; (ii) 40% of the shares subject to the option will vest the 30th consecutive date that closing trading price of the Issuer's common stock first reaches or exceeds $25.00 per share; and and (iii) 20% of the shares subject to the option will vest the 30th consecutive date that closing trading price of the Issuer's common stock first reaches or exceeds $55.00 per share, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date and as appropriately adjusted for stock splits, stock dividends, recapitalizations and the like. Read SEC document |
| November 18, 2016 Filed Nov 23, 2016 19:18 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 57,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001140361-16-087818 · doc1.xml · derivative · entry 2 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires 2026-11-18 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on November 15, 2017, and the remaining shares subject to the option vest in 36 successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| November 18, 2016 Filed Nov 23, 2016 19:18 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-087818 · doc1.xml · nonDerivative · entry 1 LOEB GARY · CIK 0001561733 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Grant of Restricted Stock Units ("RSUs"). The reporting person is entitled to one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.